Colonic Cancer Induced by 1,2-Dimethylhydrazine and Colitis
Author Information
Author(s): J.F. Chester, H.A. Gaissert, J.S. Ross, R.A. Malt, S.A. Weitzman
Primary Institution: Massachusetts General Hospital
Hypothesis
Can colitis induced by chemotactic peptides promote experimental colonic cancer?
Conclusion
Colitis significantly increases the incidence of colonic tumors in mice treated with 1,2-dimethylhydrazine.
Supporting Evidence
- Colitis was confirmed in the colons of two mice dying shortly after the last of the FNLP enemas.
- Sixty-nine percent of the mice survived to the end of the experiment.
- Colonic neoplasms occurred only in the distal half of the colon.
- Adenocarcinomas were found in 23% of mice assigned to receive DMH+FNLP.
Takeaway
When mice with colitis were given a chemical that can cause cancer, more of them got tumors than those without colitis.
Methodology
Mice were treated with 1,2-dimethylhydrazine and either chemotactic peptides or control solutions, followed by observation for tumor development.
Potential Biases
Potential bias due to high mortality in the treatment group and complications from anesthesia.
Limitations
Some mice died from complications, and autolysis prevented histological examination of some colons.
Participant Demographics
Male CDI mice, aged 35 days.
Statistical Information
P-Value
0.025
Statistical Significance
p=0.025
Want to read the original?
Access the complete publication on the publisher's website